focus -WSS

focus

author：Wikipedia 2025-09-03 09:27:47 - browse：765

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

WSS

Community Health Systems hospitals under DOJ investigation

ASCO: Palliative care found as helpful given virtually as in person

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

6 phony surgeries that take placebo to the extreme

explore

focus

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Hollywood unions extend contract negotiations for actors

ASCO: Palliative care found as helpful given virtually as in person

DIEP, the 'gold standard' of breast reconstruction, is under threat

R1 RCM gets $5.8 billion buyout offer from private equity firm

Walensky prepares to leave CDC — and Congress — behind

Alabama hospital puts IVF treatments on hold

Psychedelics group wrestles with new pharma identity

Letters to First Opinion on caregivers, digital health, and more

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

The Harvard botanist who searched for psychedelics in the Amazon

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

With trial win, GSK could get blood cancer drug back on market

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

He's a Nobel laureate. Critics say he was misleading on Covid

leisure time

explore

explore

focus